MCID: HMN021
MIFTS: 52

Human T-Cell Leukemia Virus Type 1

Categories: Rare diseases, Blood diseases, Immune diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 49
Human T Lymphotropic Virus Type 1 49
Htlv-1 49

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

NIH Rare Diseases : 49 Human T-cell leukemia virus, type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life. Last updated: 12/10/2014

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to t-cell leukemia and htlv-1 associated myelopathy/tropical spastic paraparesis. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Daclizumab and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 t-cell leukemia 31.7 CNTN2 CREB1 CRTC2 GLI2
2 htlv-1 associated myelopathy/tropical spastic paraparesis 11.4
3 infective dermatitis associated with htlv-1 11.4
4 leukemia 11.3
5 adult t-cell leukemia 10.5
6 lymphoma 10.4
7 myelopathy, htlv-1-associated 10.3
8 human immunodeficiency virus type 1 10.3
9 tropical spastic paraparesis 10.3
10 spastic paraparesis 10.3
11 spasticity 10.3
12 chromosome 16p13.3 deletion syndrome, proximal 10.1 CREB1 CREBBP EP300
13 melanoma of soft tissue 10.1 ATF1 CREB1
14 rubinstein-taybi syndrome 1 10.1 CREBBP EP300
15 hepatitis c virus 10.1
16 hepatitis 10.1
17 hepatitis c 10.1
18 ring chromosome y syndrome 10.1
19 leukemia, chronic lymphocytic 2 9.9
20 hypercalcemia, infantile, 1 9.9
21 leukemia, chronic lymphocytic 9.9
22 retinoblastoma 9.9
23 rheumatoid arthritis 9.9
24 small cell cancer of the lung 9.9
25 lung cancer 9.9
26 immunodeficiency-centromeric instability-facial anomalies syndrome 1 9.9
27 mental retardation, x-linked, syndromic, snyder-robinson type 9.9
28 cerebellar degeneration-related autoantigen 3 9.9
29 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
30 multiple mitochondrial dysfunctions syndrome 5 9.9
31 arthritis 9.9
32 t-cell large granular lymphocyte leukemia 9.9
33 gastric lymphoma 9.9
34 graves' disease 9.9
35 uveitis 9.9
36 arthropathy 9.9
37 borna disease 9.9
38 neuronitis 9.9
39 herpes simplex 9.9
40 stomatitis 9.9
41 glioblastoma 9.9
42 large granular lymphocyte leukemia 9.9
43 leukemia, b-cell, chronic 9.9
44 pituitary tumors 9.9
45 endotheliitis 9.9
46 human t-cell leukemia virus type 2 9.7 CNTN2 CREB1 CREBBP EP300 NFKB1
47 helicobacter pylori infection 9.7 CHUK JUN NFKB1
48 prostate cancer 8.5 CDKN1A CHUK CREB1 CREBBP EP300 JUN

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 EP300 CREB1 CREBBP CDKN1A CRTC1 CRTC2
2 growth/size/body region MP:0005378 10.1 EP300 CREB1 CREBBP CDKN1A CRTC1 CHUK
3 endocrine/exocrine gland MP:0005379 10.09 EP300 CREB1 CREBBP CDKN1A CRTC1 CHUK
4 embryo MP:0005380 10 EP300 CREB1 CREBBP CDKN1A CHUK GLI2
5 craniofacial MP:0005382 9.95 EP300 CREBBP CDKN1A CHUK NFKB1 GLI2
6 limbs/digits/tail MP:0005371 9.8 CREBBP CDKN1A CHUK CRTC3 CNTN2 GLI2
7 liver/biliary system MP:0005370 9.8 CREBBP CDKN1A CRTC2 CHUK CRTC3 JUN
8 muscle MP:0005369 9.7 EP300 CREB1 CREBBP CDKN1A CRTC3 GLI2
9 respiratory system MP:0005388 9.56 EP300 CREB1 GLI2 CREBBP CDKN1A CHUK
10 skeleton MP:0005390 9.23 CREB1 CREBBP CDKN1A CHUK CRTC3 NFKB1

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
2 Immunoglobulins Phase 4,Phase 1,Phase 2
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
4 Antibodies Phase 4,Phase 1,Phase 2
5
Zidovudine Approved Phase 2, Phase 3,Phase 1,Early Phase 1 30516-87-1 35370
6
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
7
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
8
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
10
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
11
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
12 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
13 Anticonvulsants Phase 3,Phase 1,Phase 2
14 Raltegravir Potassium Phase 2, Phase 3,Phase 1,Early Phase 1
15 Reverse Transcriptase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
16 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
17 GABA Agents Phase 3,Phase 1,Phase 2
18 Tranquilizing Agents Phase 3,Phase 1,Phase 2
19 Cyclosporins Phase 2, Phase 3
20 HIV Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
21 Vasodilator Agents Phase 3
22 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
23 Dermatologic Agents Phase 2, Phase 3
24 Anti-HIV Agents Phase 2, Phase 3, Phase 1, Early Phase 1
25 Phosphodiesterase Inhibitors Phase 3
26 Anti-Infective Agents Phase 2, Phase 3, Phase 1, Early Phase 1
27 Antifungal Agents Phase 2, Phase 3
28 Platelet Aggregation Inhibitors Phase 3
29 Antimanic Agents Phase 3,Phase 1,Phase 2
30 Antimetabolites Phase 2, Phase 3,Phase 1,Early Phase 1
31 Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
32 Protective Agents Phase 3
33 Anti-Retroviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
34 Psychotropic Drugs Phase 3,Phase 1,Phase 2
35 Radiation-Protective Agents Phase 3
36 Antioxidants Phase 3
37 Antirheumatic Agents Phase 2, Phase 3,Phase 1
38 Calcineurin Inhibitors Phase 2, Phase 3
39 Antiviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
40
protease inhibitors Phase 2, Phase 3
41 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
42 HIV Protease Inhibitors Phase 2, Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
44
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
45
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
46
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
47
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
48
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
49
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
50
alemtuzumab Approved, Investigational Phase 2,Phase 1 216503-57-0

Interventional clinical trials:

(show top 50) (show all 57)

# Name Status NCT ID Phase Drugs
1 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
4 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine
5 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
6 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00773292 Phase 2, Phase 3 ciclosporin
7 Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM) Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
8 A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) Recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
9 Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Recruiting NCT01854762 Phase 2, Phase 3 Raltegravir;Lopinavir/Ritonavir
10 Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
11 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
12 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
13 Anti-Tac for Treatment of Leukemia Completed NCT00001941 Phase 1, Phase 2
14 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
15 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
16 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
17 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
18 Ruxolitinib for Adult T-Cell Leukemia Recruiting NCT01712659 Phase 2 Ruxolitinib
19 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
20 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
21 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
22 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Suspended NCT02631746 Phase 2
23 Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 1, Phase 2 Valproic Acid;Zidovudine
24 The HAM Infliximab Study Terminated NCT00823641 Phase 2 Infliximab
25 Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Withdrawn NCT01620736 Phase 2 Raltegravir
26 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
27 Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00076843 Phase 1 Hu MiK-Beta-1
28 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Completed NCT01169298 Phase 1 Lenalidomide
29 Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM) Recruiting NCT02961712 Phase 1
30 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
31 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Unknown status NCT01754311
32 Urological Physical Therapy in HTLV-1 With Urinary Symptoms Unknown status NCT01651819
33 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
34 Notification of Donors With Positive Microbiology Markers Unknown status NCT01050881
35 Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica Completed NCT00339807
36 A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis Completed NCT00340821
37 MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00034723
38 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa Completed NCT02439918
39 Dual Algorithm Post Market Clinical Study Completed NCT03146013
40 Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 Completed NCT00339638
41 Neuroimmunology Branch Repository Completed NCT01581567
42 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
43 Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia Completed NCT01520246
44 Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
45 Late Effects of Treatment for Sarcomas in Children Completed NCT00006515
46 Retrovirus Epidemiology Donor Study-II (REDS-II) Completed NCT00097006
47 Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection Recruiting NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
48 Evaluation of Patients With HAM/TSP Recruiting NCT00001778
49 Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus Recruiting NCT02877030
50 Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Recruiting NCT00001582

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

38
T Cells, Breast, Brain, Nk Cells, Liver, Monocytes, B Cells

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 452)
# Title Authors Year
1
Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor. ( 29212930 )
2018
2
Failure to prevent human T-cell leukemia virus type 1 mother-to-child transmission in Japan. ( 28211219 )
2017
3
Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging. ( 28753950 )
2017
4
Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo. ( 29186194 )
2017
5
Human T Cell Leukemia Virus Type 1 and Eye Diseases. ( 28263674 )
2017
6
RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells. ( 28478312 )
2017
7
Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line. ( 28615198 )
2017
8
Human T Cell Leukemia Virus Type 1: Persistence and Pathogenesis. ( 29144838 )
2017
9
Human T-Cell Leukemia Virus Type 1 Infection and Adult T-Cell Leukemia. ( 29052136 )
2017
10
Effects of expressing human T-cell leukemia virus type 1 (HTLV-I) oncoprotein Tax on DOK1, DOK2 and DOK3 gene expression in mice. ( 28302940 )
2017
11
Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results. ( 28701419 )
2017
12
The Tax-Inducible Actin-Bundling Protein Fascin Is Crucial for Release and Cell-to-Cell Transmission of Human T-Cell Leukemia Virus Type 1 (HTLV-1). ( 27776189 )
2016
13
Permissive Sense and Antisense Transcription from the 5' and 3' Long Terminal Repeats of Human T-Cell Leukemia Virus Type 1. ( 26792732 )
2016
14
Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. ( 27677902 )
2016
15
Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. ( 26819304 )
2016
16
Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel cis-Acting Regulatory Sequence. ( 26581997 )
2016
17
Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation. ( 26819312 )
2016
18
Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. ( 26996829 )
2016
19
Enhanced Stabilization of MCL1 by the Human T-Cell Leukemia Virus Type 1 bZIP Factor Is Modulated by Blocking the Recruitment of Cullin 1 to the SCF Complex. ( 27697867 )
2016
20
Induction of Cell Death in Growing Human T-Cells and Cell Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1 Tax. ( 26829041 )
2016
21
Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB. ( 26739459 )
2016
22
Regulation of the tumor marker Fascin by the viral oncoprotein Tax of human T-cell leukemia virus type 1 (HTLV-1) depends on promoter activation and on a promoter-independent mechanism. ( 26363219 )
2015
23
Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. ( 25473052 )
2015
24
Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease. ( 25889320 )
2015
25
Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study. ( 26292315 )
2015
26
Advanced human T-cell leukemia virus type 1 carriersA and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. ( 25703103 )
2015
27
Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence. ( 26198240 )
2015
28
Viral Source-Independent High Susceptibility of Dendritic Cells to Human T-Cell Leukemia Virus Type 1 Infection Compared to That of T Lymphocytes. ( 26269171 )
2015
29
Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-I_B inhibitor A20 and constitutive NF-I_B signaling. ( 25774694 )
2015
30
miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. ( 25568327 )
2015
31
Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. ( 26174324 )
2015
32
Human T-cell leukemia virus type 1 Tax oncoprotein represses the expression of the BCL11B tumor suppressor in T-cells. ( 25613934 )
2015
33
Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. ( 26608313 )
2015
34
Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. ( 25883717 )
2015
35
SIRT1 Suppresses Human T-Cell Leukemia Virus Type 1 Transcription. ( 26063426 )
2015
36
Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. ( 26324707 )
2015
37
Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission. ( 24284316 )
2014
38
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. ( 24403582 )
2014
39
Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. ( 24792037 )
2014
40
Reevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors. ( 25363675 )
2014
41
Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis. ( 24352466 )
2014
42
Human T-cell leukemia virus type 1 Tax protein interacts with and mislocalizes the PDZ domain protein MAGI-1. ( 23279616 )
2013
43
p53 dysfunction precedes the activation of nuclear factor-I_B during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. ( 23633516 )
2013
44
HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-I_B activation and HTLV-1 replication. ( 24109220 )
2013
45
The cellular autophagy pathway modulates human T-cell leukemia virus type 1 replication. ( 23175371 )
2013
46
Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. ( 23606621 )
2013
47
Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. ( 24060211 )
2013
48
CD69 overexpression by human T-cell leukemia virus type 1 Tax transactivation. ( 23507197 )
2013
49
Molecular study of HBZ and gp21 human T cell leukemia virus type 1 proteins isolated from different clinical profile infected individuals. ( 23800288 )
2013
50
Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1. ( 23888327 )
2013

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ATF1 CDKN1A CHUK CREB1 CREBBP EP300
2
Show member pathways
13.76 CDKN1A CHUK CREB1 CREBBP EP300 JUN
3
Show member pathways
13.76 CDKN1A CHUK CREB1 CREBBP EP300 JUN
4
Show member pathways
13.58 CDKN1A CHUK CREB1 CREBBP EP300 JUN
5
Show member pathways
13.26 ATF1 CHUK CREB1 CREBBP EP300 JUN
6
Show member pathways
13.09 CREB1 CREBBP EP300 GLI2 JUN NFKB1
7
Show member pathways
13.08 CDKN1A CHUK CREB1 CREBBP EP300 JUN
8
Show member pathways
13.02 CDKN1A CHUK CREB1 CREBBP CRTC2 EP300
9
Show member pathways
13.01 CHUK CREBBP EP300 JUN NFKB1
10
Show member pathways
12.93 CHUK CREBBP EP300 JUN NFKB1
11
Show member pathways
12.92 ATF1 CHUK CREB1 JUN NFKB1
12
Show member pathways
12.89 CREB1 CREBBP CRTC1 CRTC2 CRTC3
13
Show member pathways
12.85 CHUK CREBBP EP300 JUN NFKB1 XPO1
14
Show member pathways
12.84 CHUK CREB1 CREBBP EP300 NFKB1
15 12.83 CDKN1A CHUK CREBBP EP300 GLI2 JUN
16
Show member pathways
12.82 ATF1 CDKN1A CHUK CREB1 JUN NFKB1
17
Show member pathways
12.72 CHUK CREB1 CREBBP JUN NFKB1
18
Show member pathways
12.66 CDKN1A CHUK CREBBP EP300 NFKB1
19
Show member pathways
12.61 CDKN1A CREB1 JUN NFKB1
20
Show member pathways
12.58 ATF1 CREB1 JUN NFKB1
21 12.56 CDKN1A CREBBP EP300 NFKB1
22
Show member pathways
12.55 CREB1 CREBBP EP300 JUN NFKB1
23
Show member pathways
12.54 CDKN1A CREBBP EP300 JUN NFKB1
24
Show member pathways
12.49 CHUK CREB1 JUN NFKB1
25
Show member pathways
12.49 CHUK CREB1 CREBBP EP300 JUN NFKB1
26 12.48 CHUK CREB1 CREBBP JUN
27
Show member pathways
12.48 CHUK CREBBP EP300 NFKB1
28
Show member pathways
12.48 CHUK CREBBP EP300 NFKB1
29
Show member pathways
12.48 CHUK CREB1 JUN NFKB1
30
Show member pathways
12.47 CDKN1A CHUK CREB1 CREBBP EP300 JUN
31
Show member pathways
12.45 CHUK CREB1 JUN NFKB1
32
Show member pathways
12.45 CDKN1A CHUK CREB1 EP300 NFKB1
33
Show member pathways
12.44 CHUK EP300 JUN NFKB1
34
Show member pathways
12.44 CHUK CREB1 JUN NFKB1
35
Show member pathways
12.42 CDKN1A CREB1 CREBBP EP300 GLI2
36
Show member pathways
12.39 CHUK CREB1 JUN NFKB1
38
Show member pathways
12.36 CREB1 CREBBP EP300 JUN NFKB1
39
Show member pathways
12.33 ATF1 CHUK EP300 JUN NFKB1
40
Show member pathways
12.32 CHUK CREB1 JUN NFKB1
41 12.3 CREB1 CREBBP EP300 NFKB1
42 12.3 CDKN1A CREB1 CREBBP EP300 JUN NFKB1
43
Show member pathways
12.28 CDKN1A JUN NFKB1 XPO1
44
Show member pathways
12.27 CHUK CREBBP EP300 NFKB1
45
Show member pathways
12.26 CHUK CREB1 JUN NFKB1
46 12.23 CREB1 CREBBP EP300 JUN NFKB1
47
Show member pathways
12.19 CDKN1A CHUK EP300 JUN NFKB1
48
Show member pathways
12.19 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
49
Show member pathways
12.18 CHUK CREB1 CREBBP JUN NFKB1
50 12.17 CDKN1A CHUK CREBBP EP300 JUN NFKB1

GO Terms for Human T-Cell Leukemia Virus Type 1

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 APOBEC3B ATF1 CDKN1A CHUK CREB1 CREBBP
2 transcription factor complex GO:0005667 9.46 ATF1 CREB1 EP300 JUN
3 nucleoplasm GO:0005654 9.44 ATF1 CDKN1A CHUK CREB1 CREBBP CRTC1

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.99 ATF1 CREB1 EP300 GLI2 JUN NFKB1
2 response to drug GO:0042493 9.88 CDKN1A CHUK CREB1 JUN XPO1
3 regulation of cell cycle GO:0051726 9.79 CDKN1A EP300 JUN
4 response to organic cyclic compound GO:0014070 9.79 ATF1 CDKN1A JUN
5 rhythmic process GO:0048511 9.76 CREB1 CREBBP CRTC1 EP300
6 circadian rhythm GO:0007623 9.74 CREB1 EP300 JUN
7 protein homotetramerization GO:0051289 9.73 CRTC1 CRTC2 CRTC3
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.73 CHUK CREBBP EP300 NFKB1
9 positive regulation of type I interferon production GO:0032481 9.72 CREBBP EP300 NFKB1
10 protein kinase B signaling GO:0043491 9.71 CDKN1A CHUK CREB1
11 positive regulation of DNA replication GO:0045740 9.7 ATF1 GLI2 JUN
12 positive regulation of transcription, DNA-templated GO:0045893 9.7 CHUK CREB1 CREBBP EP300 GLI2 JUN
13 response to organic substance GO:0010033 9.62 CDKN1A CHUK CREB1 JUN
14 energy homeostasis GO:0097009 9.61 CRTC1 CRTC3
15 positive regulation by host of viral transcription GO:0043923 9.6 EP300 JUN
16 response to muscle stretch GO:0035994 9.59 JUN NFKB1
17 positive regulation of long-term synaptic potentiation GO:1900273 9.58 CREB1 CRTC1
18 protein acetylation GO:0006473 9.58 CREBBP EP300
19 viral process GO:0016032 9.5 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
20 N-terminal peptidyl-lysine acetylation GO:0018076 9.49 CREBBP EP300
21 positive regulation of CREB transcription factor activity GO:0032793 9.43 CRTC1 CRTC2 CRTC3
22 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 ATF1 CHUK CREB1 CREBBP CRTC1 CRTC2
23 regulation of transcription, DNA-templated GO:0006355 10.1 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3
24 transcription, DNA-templated GO:0006351 10.07 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 DNA binding transcription factor activity GO:0003700 9.97 ATF1 CREB1 CREBBP GLI2 JUN NFKB1
2 sequence-specific DNA binding GO:0043565 9.88 ATF1 CREB1 GLI2 JUN NFKB1
3 transcription regulatory region DNA binding GO:0044212 9.76 CREB1 GLI2 JUN NFKB1
4 chromatin binding GO:0003682 9.73 CREBBP CRTC2 EP300 GLI2 JUN NFKB1
5 transcription factor binding GO:0008134 9.63 CREB1 CREBBP EP300 GLI2 JUN NFKB1
6 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.61 CREB1 JUN NFKB1
7 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.58 ATF1 CREB1 JUN
8 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.55 CREB1 JUN
9 acetyltransferase activity GO:0016407 9.54 CREBBP EP300
10 transcription cofactor activity GO:0003712 9.54 CREB1 CREBBP EP300
11 cAMP response element binding GO:0035497 9.51 CREB1 JUN
12 peptide N-acetyltransferase activity GO:0034212 9.32 CREBBP EP300
13 cAMP response element binding protein binding GO:0008140 9.13 CRTC1 CRTC2 CRTC3
14 RNA polymerase II activating transcription factor binding GO:0001102 8.92 CREB1 CREBBP EP300 JUN
15 identical protein binding GO:0042802 10 ATF1 BST2 CNTN2 CREB1 JUN NFKB1

Sources for Human T-Cell Leukemia Virus Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....